<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326517</url>
  </required_header>
  <id_info>
    <org_study_id>UR 18-00008</org_study_id>
    <nct_id>NCT04326517</nct_id>
  </id_info>
  <brief_title>Factors Associated To Intensive Care Admission And Mortality In Patients With Emphysematous Pyelonephritis</brief_title>
  <official_title>Microbiologic Profile And Factors Associated To Intensive Care Admission And Mortality In Patients With Emphysematous Pyelonephritis: A 10-Year Experience In A Tertiary Care Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emphysematous pyelonephritis is a lifethreatening necrotizing infection of the kidney
      characterized by accumulation of gas in the renal parenchyma and within the surrounding
      tissues. The aim of the study is to report the outcome of the management of this condition at
      the investigators institution and to determine the microbiological characteristics,
      antibiotic resistance patterns, and to analyze factors predicting mortality and intensive
      care unit admission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are planning to perform a retrospective study analyzing cases of
      emphysematous pyelonephritis from a single tertiary care institution in the north of Mexico
      in the period of 2011-2021. The diagnosis of emphysematous pyelonephritis is confirmed by
      computed tomography. Demographic, clinical, biochemical, therapeutic management, and outcomes
      will be collected. Variables will be analyzed to determine factors associated with admission
      to intensive care unit and mortality. Urine cultures will be analyzed and drug resistance
      profile will be determined using microdilution plate. Clinical and demographic
      characteristics will be analyzed using Chi square test for categorical variables, and T-test
      for numerical variables. Statistical significance is set at p&lt;0.05. Statistical analysis will
      be performed with the SPSS software version 20.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with admission to Intensive care unit</measure>
    <time_frame>10 years</time_frame>
    <description>Patients with criteria to admit to intensive care unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of mortality</measure>
    <time_frame>10 years</time_frame>
    <description>Death cases during hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibiotic susceptibility</measure>
    <time_frame>10 years</time_frame>
    <description>Drug resistance profile will be determined using microdilution plate.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Emphysematous Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Emphysematous pyelonephritis</arm_group_label>
    <description>This is a single-group cohort study. A sub-classification will be used in order to differentiate patients that did not require intensive care, the ones who admitted to intensive care and mortality.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nephrectomy</intervention_name>
    <description>Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.</description>
    <arm_group_label>Emphysematous pyelonephritis</arm_group_label>
    <other_name>ureteral stent</other_name>
    <other_name>percutaneous drainage</other_name>
    <other_name>medical treatment</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a confirmatory diagnosis using emphysematous pyelonephritis by computed
        tomography are included, as well as signs and symptoms of upper urinary tract infection and
        data of systemic inflammatory response. Participants are usually admitted to the emergency
        room and recruited for analysis during hospitalization.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Emphysematous pyelonephritis confirmed with computed tomography

          -  Systemic inflammatory response

          -  Urinary tract infection symptoms

          -  Complete medical records

          -  Both genders included

          -  &gt;18 years old

        Exclusion Criteria:

          -  Other infectious causes

          -  Asymptomatic bacteriuria

          -  Incomplete medical records

          -  Endourologic procedure 3 months before recruitment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrián Gutiérrez-González, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autónoma de Nuevo León</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose I Robles-Torres, M.D.</last_name>
    <phone>+526531191450</phone>
    <email>ivan.robles25@live.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marco A Ocaña-Munguía, M.D.</last_name>
    <phone>+528113112108</phone>
    <email>mocana94@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. José Eleuterio González&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Outside U.S./Canada</state>
        <zip>64634</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose I Robles-Torres, M.D.</last_name>
      <phone>+526531191450</phone>
      <email>ivan.robles25@live.com</email>
    </contact>
    <contact_backup>
      <last_name>Marco A Ocaña-Munguía, M.D.</last_name>
      <phone>+528113112108</phone>
      <email>mocana94@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Michaeli J, Mogle P, Perlberg S, Heiman S, Caine M. Emphysematous pyelonephritis. J Urol. 1984 Feb;131(2):203-8. Review.</citation>
    <PMID>6366247</PMID>
  </results_reference>
  <results_reference>
    <citation>Pontin AR, Barnes RD, Joffe J, Kahn D. Emphysematous pyelonephritis in diabetic patients. Br J Urol. 1995 Jan;75(1):71-4.</citation>
    <PMID>7850302</PMID>
  </results_reference>
  <results_reference>
    <citation>Ubee SS, McGlynn L, Fordham M. Emphysematous pyelonephritis. BJU Int. 2011 May;107(9):1474-8. doi: 10.1111/j.1464-410X.2010.09660.x. Epub 2010 Sep 14. Review.</citation>
    <PMID>20840327</PMID>
  </results_reference>
  <results_reference>
    <citation>Kumar A, Turney JH, Brownjohn AM, McMahon MJ. Unusual bacterial infections of the urinary tract in diabetic patients--rare but frequently lethal. Nephrol Dial Transplant. 2001 May;16(5):1062-5.</citation>
    <PMID>11328918</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000 Mar 27;160(6):797-805.</citation>
    <PMID>10737279</PMID>
  </results_reference>
  <results_reference>
    <citation>Falagas ME, Alexiou VG, Giannopoulou KP, Siempos II. Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis. J Urol. 2007 Sep;178(3 Pt 1):880-5; quiz 1129. Epub 2007 Jul 16.</citation>
    <PMID>17631348</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang JJ, Chen KW, Ruaan MK. Mixed acid fermentation of glucose as a mechanism of emphysematous urinary tract infection. J Urol. 1991 Jul;146(1):148-51.</citation>
    <PMID>2056576</PMID>
  </results_reference>
  <results_reference>
    <citation>Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N'Dow J; ABACUS Research Group. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol. 2008 May;179(5):1844-9. doi: 10.1016/j.juro.2008.01.019. Epub 2008 Mar 19. Review.</citation>
    <PMID>18353396</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Adrián Gutiérrez González</investigator_full_name>
    <investigator_title>Head of Urology Department</investigator_title>
  </responsible_party>
  <keyword>emphysematous pyelonephritis</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>mortality</keyword>
  <keyword>risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>An e-mail contact of the research party will be published in order to share information of our data, excel databases and other type of information.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>after recruitment period has concluded.</ipd_time_frame>
    <ipd_access_criteria>By e-mail, any author will be available in order to support and facilitate requested information.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

